Why Is TARSUS PHARMACEUTICA (TARS) Stock Moving Today?

TARS stock is moving lower today, down 3.0% at the open, as the market reacts to the departure of Chief Commercial Officer Aziz Mottiwala. The executive transition, announced in a July 13 filing, has drawn mixed sentiment from news outlets and analysts. The stock has traded between $56.20 and $59.26 in the session so far, with volume at 0.2 million shares, below its 3-month average.

What Happened

Tarsus Pharmaceuticals disclosed the departure of Aziz Mottiwala, its Chief Commercial Officer, who is leaving to become CEO of a public medical device company, according to Seeking Alpha. The company also announced the transition in a press release cited by Business Insider. The SEC 8-K filing on July 13 details the executive change under Item 5.02. TipRanks reported the move as a leadership update without specifying the new role, while the AI sentiment on the Seeking Alpha headline was notably lower at 34.

Recent insider transactions show a pattern of selling by executives and directors over the past month, with four sales totaling $2.5 million reported to the SEC. The stock has also been under pressure from short sellers, as noted in a Benzinga report alleging an illegal copay scheme and another highlighting a short position by Culper Research.

What The Data Shows

The stock opened with a 3.0% gap down from the prior close of $59.31, reaching a high of $59.26 before retreating. It has traded in a narrow range, with the last price at $56.52. The 52-week range is $38.51 to $85.25, and the stock has declined 2.5% over the last eight sessions. Tarsus Pharmaceuticals has a market cap of $2.5 billion and is unprofitable, with a trailing 12-month EPS of -1.13 and a net margin of -9.0%. Revenue has grown 129.0% TTM, but the stock's beta of 0.50 suggests it is less volatile than the broader market.

What To Watch

Investors should monitor the company's next steps in commercial leadership and the impact of recent insider selling. Coverage from HC Wainwright, which maintains a buy rating and $88 price target, may provide further insight into the stock's direction.